264 related articles for article (PubMed ID: 35947358)
21. Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.
Lopedote P; Shadman M
Cancer Manag Res; 2023; 15():257-264. PubMed ID: 36941881
[TBL] [Abstract][Full Text] [Related]
22. Blinatumomab: first global approval.
Sanford M
Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
[TBL] [Abstract][Full Text] [Related]
23. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
24. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
[TBL] [Abstract][Full Text] [Related]
25. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
26. Teclistamab: First Approval.
Kang C
Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
[TBL] [Abstract][Full Text] [Related]
27. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
28. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P; Cohen JB; Kahl BS; Burack WR; Koff JL; Mun Y; Masaquel A; Wu M; Wei MC; Shewade A; Li J; Cerhan JR; Link BK; Flowers CR
Haematologica; 2023 Nov; ():. PubMed ID: 38031804
[TBL] [Abstract][Full Text] [Related]
29. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
McGough SF; Shamas N; Wang J; Jaber M; Swarup B; Blanchet Zumofen MH; Lautié B; Parreira J; Wei MC; Shewade A
Leuk Lymphoma; 2023 Dec; 64(14):2269-2278. PubMed ID: 37840271
[TBL] [Abstract][Full Text] [Related]
31. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
33. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
[TBL] [Abstract][Full Text] [Related]
34. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Nuvvula S; Dahiya S; Patel SA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
[TBL] [Abstract][Full Text] [Related]
35. Epcoritamab: First Approval.
Frampton JE
Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
[TBL] [Abstract][Full Text] [Related]
36. Targeted Therapies for Follicular Lymphoma.
Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
[TBL] [Abstract][Full Text] [Related]
37. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
39. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
40. Copanlisib: First Global Approval.
Markham A
Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
